Acotec Scientific Holdings Limited announced that on December 23, 2022, the Group received the registration approvals from the PRC National Products Administration for YAN, a product designed for dilation in coronary artery or coronary artery bypass vessels stenosis to improve myocardial perfusion. YAN is also indicated for dilation of coronary artery occlusive lesions to restore coronary blood flow of ST-segment elevation myocardial infarction (STMI) patients. The Company will carry out marketing activities in PRC market when appropriate.
Acotec Scientific Holdings Limited
Equities
6669
KYG0096M1096
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.23 HKD | +2.13% | -2.66% | -44.77% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-44.77% | 244M | |
+72.39% | 12.32B | |
-18.22% | 7.96B | |
+16.84% | 7.25B | |
+3.25% | 5.84B | |
+8.16% | 5.11B | |
+19.97% | 4.28B | |
-19.84% | 4B | |
-42.79% | 2.15B | |
+1.36% | 2.01B |
- Stock Market
- Equities
- 6669 Stock
- News Acotec Scientific Holdings Limited
- Acotec Scientific Holdings Limited Receives Approval for YAN by PRC National Medical Products administration